title: TH and NPY in sympathetic neurovascular cultures: role of LIF and NT-3.
abstract: The sympathetic nervous system is an important determinant of vascular function. The effects of the sympathetic nervous system are mediated via release of neurotransmitters and neuropeptides from postganglionic sympathetic neurons. The present study tests the hypothesis that vascular smooth muscle cells (VSM) maintain adrenergic neurotransmitter/neuropeptide expression in the postganglionic sympathetic neurons that innervate them. The effects of rat aortic and tail artery VSM (AVSM and TAVSM, respectively) on neuropeptide Y (NPY) and tyrosine hydroxylase (TH) were assessed in cultures of dissociated sympathetic neurons. AVSM decreased TH (39 +/- 12% of control) but did not affect NPY. TAVSM decreased TH (76 +/- 10% of control) but increased NPY (153 +/- 20% of control). VSM expressed leukemia inhibitory factor (LIF) and neurotrophin-3 (NT-3), which are known to modulate NPY and TH expression. Sympathetic neurons innervating blood vessels expressed LIF and NT-3 receptors. Inhibition of LIF inhibited the effect of AVSM on TH. Inhibition of neurotrophin-3 (NT-3) decreased TH and NPY in neurons grown in the presence of TAVSM. These data suggest that vascular-derived LIF decreases TH and vascular-derived NT-3 increases or maintains NPY and TH expression in postganglionic sympathetic neurons. NPY and TH in vascular sympathetic nerves are likely to modulate NPY and/or norepinephrine release from these nerves and are thus likely to affect blood flow and blood pressure. The present studies suggest a novel mechanism whereby VSM would modulate sympathetic control of vascular function.
authors.affiliation: Dept. of Pharmacology, Univ. of Vermont, 89 Beaumont Ave., Given Bldg., Burlington, VT 05405, USA. Deborah.Damon@uvm.edu
authors.forename: Deborah H
authors.initials: DH
authors.lastname: Damon
mesh_terms: D000818:Animals; D000831:Animals, Newborn; D000906:Antibodies; D002478:Cells, Cultured; D018920:Coculture Techniques; D050822:Cytokine Receptor gp130 / Q000378:metabolism; D005260:Female; D053605:Leukemia Inhibitory Factor / Q000276:immunology / Q000378:metabolism*; D008297:Male; D009131:Muscle, Smooth, Vascular / Q000201:enzymology / Q000294:innervation / Q000378:metabolism*; D032389:Myocytes, Smooth Muscle / Q000201:enzymology / Q000378:metabolism*; D009414:Nerve Growth Factors / Q000378:metabolism*; D009478:Neuropeptide Y / Q000378:metabolism*; D019899:Paracrine Communication; D051381:Rats; D017207:Rats, Sprague-Dawley; D020812:Receptor, trkC / Q000378:metabolism; D017475:Receptors, Nerve Growth Factor / Q000378:metabolism; D053606:Receptors, OSM-LIF / Q000378:metabolism; D011993:Recombinant Fusion Proteins / Q000378:metabolism; D017779:Sympathetic Fibers, Postganglionic / Q000201:enzymology / Q000378:metabolism*; D014446:Tyrosine 3-Monooxygenase / Q000378:metabolism*
chemical_list: D000906:Antibodies; D053605:Leukemia Inhibitory Factor; D009414:Nerve Growth Factors; D009478:Neuropeptide Y; D017475:Receptors, Nerve Growth Factor; D053606:Receptors, OSM-LIF; D011993:Recombinant Fusion Proteins; D050822:Cytokine Receptor gp130; D014446:Tyrosine 3-Monooxygenase; D020812:Receptor, trkC